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. It is now appreciated that most of the clinical and pathological features of MDS are the direct result of recurrent acquired somatic genetic lesions (FIG. 1) . Although MDS and related myeloproliferative neoplasms (MPNs) are defined by distinct clinical and morphological criteria, they share many of the same genetic mutations, and the composite genotype of individual cases -including the specific genes mutated, the order in which they were mutated and the interactions between clones and subclones -is likely to underlie these phenotypic differences
. In addition, there are several rare familial syndromes associated with a predisposition to early onset MDS 2 
.
MDS is among the most common of the haematological malignancies, with current estimates placing its incidence in the United States as between 5.3 and 13.1 cases per 100,000 persons 3 . In adults, advanced age is the predominant risk factor for developing MDS, with a median age at diagnosis of 71-76 years 4, 5 . Precise enumeration of the incidence of MDS has been challenging because it was not independently recorded in the National Cancer Institute's Survey, Epidemiology and End Results (SEER) cancer databases until 2001; the true prevalence is probably underestimated, as a bone marrow biopsy is required for diagnosis and many older patients with mild cytopenias do not undergo marrow evaluation. The limited data available suggest that the incidence is increasing over time, which may be due to an ageing population, improving survival after treatments for other neoplasms that place patients at risk of subsequent development of therapy-related MDS (t-MDS) and increased awareness of MDS among general practitioners 5 . Although patients with MDS can be asymptomatic at diagnosis, identified only by the incidental discovery of cytopenias, many patients present with clinical symptoms such as fatigue, often related to anaemia, bleeding owing to thrombocytopenia and fevers or recurrent infections as a result of neutropenia. The clinical course is variable: some patients live for many years with minimal therapy, whereas others rapidly progress to AML. Morbidity and mortality in MDS are related primarily to complications arising from cytopenias and transformation to AML. The risk of either event can be assessed using one of several prognostic systems, including the International Prognostic Scoring System (IPSS), the revised IPSS (IPSS-R), the WHO-based Prognostic Scoring System (WPSS) and the MD Anderson Comprehensive Scoring System (MDA-CSS) [6] [7] [8] . Although the IPSS and, more recently, the IPSS-R have become the most widely used, these scoring systems are largely interchangeable and all take into account some combination of the degree of cytopenia, the proportion of bone marrow blasts and the karyotype. These prognostic scoring TET2  ASXL1  DNMT3A  EZH2  BCOR  IDH2  IDH1  BCORL1  ATRX   STAG2  CTCF  SMC3  SMC1A  RAD21   SF3B1  SRSF2  U2AF1  ZRSR2  LUC7L2  U2AF2  PRPF8  SF1   RUNX1  CUX1  ETV6  NPM1  GATA2  WT1  CEBPA   TP53  PPM1D   JAK2  NF1  NRAS  CBL  MPL  KRAS  FLT3  GNAS  KIT  PTPN11  GNB1   BRCC3  ATM , MDS 9, 25, 26, 35 , secondary acute myeloid leukaemia (sAML) 28 , acute myeloid leukaemia (AML) [192] [193] [194] and aplastic anaemia (AA) 45 . alloHSCT, allogeneic haematopoietic stem cell transplantation; ASXL1, additional sex combs-like 1; ATM, ataxia telangiectasia mutated; BCOR, BCL6 co-repressor; BCORL1, BCL6 co-repressor-like 1; BRCC3, BRCA1/BRCA2-containing complex subunit 3; CEBPA, CCAAT/enhancer binding protein α; CMML, chronic myelomonocytic leukaemia; CTCF, CCCTC-binding factor; CUX1, cut-like homeobox 1; DNMT3A, DNA methyltransferase 3A; ETV6, ETS variant 6; EZH2, enhancer of zeste 2; FANCL, Fanconi anaemia complementation group L; FLT3, fms related tyrosine kinase 3; GATA2, GATA binding protein 2; GNB1, G protein subunit β1; HMAs, hypomethylating agents; IDH1, isocitrate dehydrogenase 1; JAK2, Janus kinase 2; JMML, juvenile myelomonocytic leukaemia; LUC7L2, LUC7 like 2, pre-mRNA splicing factor; MonoMAC, monocytosis with increased susceptibility to mycobacterial infections; MPL, gene that encodes the thrombopoietin receptor; MPN, myeloproliferative neoplasm; NF1, nuclear factor 1; NPM1, nucleophosmin; PIGA, phosphatidylinositol glycan anchor biosynthesis class A; PPM1D, protein phosphatase, Mg 2+ / Mn 2+ -dependent 1D; PRPF8, pre-mRNA processing factor 8; PRPN11, protein tyrosine phosphatase, non-receptor type 11; RUNX1, runt related transcription factor 1; SF1, splicing factor 1; SF3B1, splicing factor 3b subunit 1; SMC1A, structural maintenance of chromosomes 1A; SRSF2, serine and arginine rich splicing factor 2; STAG2, stromal antigen 2; TET2, tet methylcytosine dioxygenase2; U2AF1, U2 small nuclear RNA auxiliary factor 1; WT1, Wilms tumour 1; ZRSR2, zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2. systems do not include information about somatic mutations in individual genes, although this genetic information can predict prognosis independently of each of the prognostic scoring systems 9, 10 . In this Review we discuss the molecular and genetic basis of MDS, beginning with initiating mutations in haematopoietic stem cells (HSCs) that lead to the development of clonal haematopoiesis. This initiating event is followed by the accumulation of additional cooperating mutations and eventual progression to overt clinical disease, including MDS and secondary AML (sAML). Finally, we discuss how our evolving understanding of the genetics of MDS provides insights into the clinical course, prognosis and treatment of patients with MDS. Although the founding genetic event in MDS pathogenesis has long been assumed to occur in a myeloidbiased HSC, patients with clonal haematopoiesis have an increased risk of developing both lymphoid and myeloid malignancies, perhaps suggesting mutational overlap or a common early precursor stem cell 12 . Many of the mutations commonly found in myeloid malignancies, such as tet methylcytosine dioxygenase 2 (TET2) and splicing factor 3b subunit 1 (SF3B1), have also been identified in lymphoid cells or have been described in various lymphomas [13] [14] [15] [16] [17] . Although most patients with MDS follow a course dominated by cytopenias and their consequences, approximately one-third progress to high-risk MDS and sAML 18 . The genetic mutations in MDS seem to be initiated in an HSC. Sequencing of sequential samples from individual patients demonstrated that in the 5q − syndrome clinical stability was associated with mutational stability 11 . Conversely, those patients who progressed to AML developed multiple new mutations in the leukaemic stem cell compartment, coupled with new myeloid progenitor (that is, non-HSC) populations that had gained self-renewal potential 11 . The expansion of self-renewal activity outside the stem cell compartment, and expansion of the population of cells with proliferative potential, are two other key steps in the transition from MDS to AML. Eradicating the mutated MDS stem cells, which are capable of maintaining the disease indefinitely, is likely to be essential to curing the disease.
Clonal haematopoiesis: initiators of disease. The presence of initiating mutations leading to clonal expansion, and thus a pre-malignant state, has long been suspected to precede the development of most malignancies (FIG. 2) . Initial studies of healthy women demonstrated
Box 1 | The spectrum of myeloid neoplasms
Myelodysplastic syndrome (MDS) is a haematological disorder within the larger spectrum of myeloid neoplasms. Other myeloid neoplasms include the myeloproliferative neoplasms (MPNs), acute myeloid leukaemia (AML) and MDS/MPN overlap syndromes. Although these were previously felt to be biologically distinct entities, it is now appreciated that there is a considerable degree of genetic overlap between them.
MPNs include chronic myeloid leukaemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), chronic neutrophilic leukaemia (CNL) and systemic mastocytosis (SM) 1 . Each has specific pathological characteristics, but all are distinguished from MDS by the absence of morphological dysplasia and normal, or more often increased, production of blood cells. All MPNs have mutations that constitutively activate signalling cascades and cytokine-independent proliferation. These include mutations in Janus kinase 2 (JAK2) (PV, ET and MF), calreticulin (CALR) (ET and MF), thrombopoietin receptor (MPL) (ET and MF), colony stimulating factor 3 receptor (CSF3R) (CNL), KIT (SM) and BCR-ABL rearrangements (CML) [115] [116] [117] [118] [119] 163 . Some myeloid neoplasms display features of both MPNs (elevated peripheral blood cell counts or bone marrow fibrosis) and MDS (morphological dysplasia) and are termed MDS/MPN overlap syndromes. These include chronic myelomonocytic leukaemia (CMML), which typically presents with peripheral blood monocytosis and dysplasia in the bone marrow; atypical CML, which clinically resembles CML but lacks a BCR-ABL rearrangement; and unclassifiable MDS/MPN overlap syndromes 1, 164 . Overlap syndromes frequently harbour concomitant MDS-associated mutations (for example, serine and arginine rich splicing factor 2 (SRSF2) and additional sex combs-like 1 (ASXL1)) and MPN-associated mutations (for example, JAK2). They may also harbour mutations not specific for any disorder (for example, tet methylcytosine dioxygenase 2 (TET2) and DNA methyltransferase 3A (DNMT3A)), as well as frequent mutations activating the RAS pathway (for example, NRAS, KRAS, CBL and protein tyrosine phosphatase, non-receptor type 11 (PTPN11)) 165 .
Although not classified as myeloid neoplasms, paroxysmal nocturnal haemoglobinuria (PNH) and aplastic anaemia (AA) can overlap with and transform into MDS and AML. PNH is defined by clonal, somatic mutations in phosphatidylinositol glycan anchor biosynthesis class A (PIGA). In AA, a subset of patients have clonal mutations in genes specifically associated with myeloid malignancy, including DNMT3A, ASXL1, JAK2 and TP53 (which encodes p53), at a relative frequency very similar to that seen in clonal haematopoiesis of indeterminate potential (CHIP) 45, 166, 167 . In addition, mutations in PIGA and BCL6 co-repressor (BCOR) are more common in AA than in CHIP and are associated with a better response to immunosuppressive therapy and improved overall survival 45 . Mutations in CHIP and myeloid malignancy genes, such as DNMT3A, ASXL1 or TP53, were associated with worse overall survival 45 . It is unclear how specific clonal somatic aberrations affect disease pathogenesis and evolution in AA and PNH and whether they can be used clinically to help differentiate AA from the morphologically related hypoplastic MDS. Clonal haematopoiesis of indeterminate potential (CHIP) . The presence of a somatic mutation associated with haematological malignancy at a variant allele fraction of at least 2% and the absence of morphological evidence of malignancy or diagnostic criteria for paroxysmal nocturnal haemoglobinuria, monoclonal gammopathy of undetermined significance or monoclonal B-lymphocytosis.
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Hazard ratio
A statistical measure that corresponds to the probability of a particular outcome attributable to a given variable compared with normal controls.
Annual risk
The probability of acquiring a condition over the course of 1 year.
skewing of X-chromosome inactivation in almost 40% of women more than 60 years of age, and a subset of these women were later found to harbour mutations in TET2, suggestive of clonal haematopoiesis driven by a somatic mutation 19 . More recently, exome sequencing of peripheral blood samples from more than 30,000 patients without known haematological malignancies demonstrated recurrent somatic myeloid malignancy-associated mutations in up to 10% of patients over the age of 65 and more than 20% of patients over the age of 90 (REFS 12, 20, 21) . This phenomenon has subsequently been termed clonal haematopoiesis of indeterminate potential (CHIP) 22 . The most common recurrently mutated genes were DNA methyltransferase 3A (DNMT3A), TET2, additional sex combs-like 1 (ASXL1), TP53 (which encodes p53), Janus kinase 2 (JAK2) and SF3B1, all of which are also mutated in MDS 12, 21 (FIG. 1) .
In these studies, the presence of CHIP was a strong predictor of the development of subsequent haematological malignancy (hazard ratio of 11.1), with an annual risk of approximately 0.5-1%, and decreased overall survival (hazard ratio for all-cause mortality of 1.4) compared with age-matched controls 12 . In two patients with CHIP who later developed AML, sequencing of bone marrow-derived DNA demonstrated that the leukaemias were clonally derived from the previously identified CHIP 21 . Importantly, however, the absolute risk of transformation to overt malignancy in patients with CHIP was low during the time periods under study, probably reflecting the need to acquire additional mutations in a relatively small pool of potential cooperating genes.
In fact, the most significant driver of decreased survival in association with CHIP was an increased propensity for thrombosis, coronary artery disease and stroke, the reason for which is unclear and remains under active investigation 12 . Despite these effects on survival, there are currently no data to suggest that screening of asymptomatic patients for the presence of CHIP is clinically indicated, especially in the absence of an intervention that could restore polyclonal haematopoiesis.
From CHIP to MDS: a blurred distinction. In a model of clonal evolution beginning with CHIP and ending in frank haematological malignancy, the transition to MDS probably involves a complex interplay between epigenetic alterations in the HSC, a dysfunctional bone marrow microenvironment (BOX 3) and the stepwise acquisition of additional driver mutations (FIG. 2) . The clinical diagnosis of MDS, as currently defined, does not incorporate somatic mutations, but is instead based on the morphology of haematopoietic cells in the bone marrow, the finding of cytogenetic abnormalities and the development of cytopenias in the peripheral blood 1 .
As currently defined, a diagnosis of CHIP requires the presence of a somatic mutation with a mutant allele fraction of at least 2% in the peripheral blood and no other evidence of a haematological malignancy 22 . In contrast, the presence of a mutation and otherwise unexplained cytopenias or borderline dysplasia is suggestive of, but does not confirm, progression to MDS, as the formal diagnosis still requires the fulfilment of specific morphological criteria 23, 24 . Approximately 35% of patients
Box 2 | Inherited bone marrow failure and MDS
Although most cases of myelodysplastic syndrome (MDS) are caused by somatic mutations, a few are due to inherited mutations that lead to increased risk of bone marrow failure 1, 2 . These typically affect patients in adolescence or early adulthood and include the following disorders.
• Diamond-Blackfan anaemia: characterized by absent erythroid precursors due to mutations in ribosomal protein genes, causing abnormal ribosome biogenesis, and rarely MDS or AML 168 .
• Telomerase complex disorders: due to mutations in genes encoding members of the telomerase complex (dyskerin pseudouridine synthase 1 (DKC1), telomerase reverse transcriptase (TERT), telomerase RNA component (TERC) and GAR1 ribonucleoprotein (GAR1) [169] [170] [171] [172] . The best known is dyskeratosis congenita (DKC), characterized by bone marrow failure, pulmonary fibrosis, oral leukoplakia, dystrophic nails, hyperpigmentation and cirrhosis.
• Familial platelet disorder with propensity to myeloid malignancy: characterized by childhood thrombocytopenia and a propensity to progress to MDS. It is caused by mutations in runt related transcription factor 1 (RUNX1), which encodes a component of the core binding factor transcriptional activator complex 101 .
• Familial thrombocytopenia and malignancy: characterized by dominantly inherited thrombocytopenia, an elevated mean corpuscular volume (MCV), and a propensity to haematological malignancies, including MDS and acute myeloid leukaemia (AML). It is caused by mutations in ETS variant 6 (ETV6) 99, 173 .
• Fanconi anaemia: an early-onset aplastic anaemia often associated with dysmorphic features, short stature and limb defects, caused by mutations in any of more than 15 genes involved in DNA repair 168 .
• Li-Fraumeni syndrome: caused by loss-of-function mutations in TP53, leading to an increased predisposition to many cancers, including MDS and AML 174 .
• Inherited GATA binding protein 2 (GATA2) mutations: a heterogeneous group of disorders, including MonoMAC syndrome (monocytosis with increased susceptibility to mycobacterial infections) 175 and Emberger syndrome (familial lymphoedema and deafness) 176 , both of which also carry a risk of early-onset MDS.
• Inherited DEAD-box helicase 41 (DDX41) mutations: associated with mild monocytosis and an increased risk of MDS and AML, with a longer latency to disease initiation (average age 62 years) than other genetic syndromes discussed here 138, 177 .
• Shwachman-Diamond syndrome (SDS): characterized by skeletal defects, pancreatic insufficiency and bone marrow failure, with risk of transformation to MDS. It is caused by mutations in the SBDS gene, which is required for normal ribosome maturation 178 .
Idiopathic cytopenias of undetermined significance (ICUS) . Cytopenias that remain unexplained after thorough evaluation and do not meet World Health Organization criteria for a haematological neoplasm.
de novo AML
Acute myeloid leukaemia (AML) that arises without a pre-existing myeloid neoplasm or a history of cytotoxic therapy. More common in younger patients and associated with an overall better prognosis.
Induction therapy
High-dose intensive chemotherapy directed at inducing remission in acute leukaemias.
Polycomb repressive complex
(PRC). Multiprotein complex involved in epigenetic repression of gene transcription.
with idiopathic cytopenias of undetermined significance (ICUS) have somatic mutations characteristic of MDS, although whether all such patients go on to develop morphological dysplasia, or have a clinical course similar to that of patients with MDS even in the absence of dysplasia, requires further study 24 . Conversely, as the full complement of mutations involved in MDS has yet to be defined, the absence of a known somatic mutation also does not exclude the diagnosis of MDS 22 . On the whole, however, MDS is a more genetically complex disease than CHIP, with most patients harbouring at least two, and sometimes many more, somatic mutations in recurrent driver genes, often with a high mutant allele fraction (>10%), at the time of diagnosis 25, 26 . The genetic lesions that initiate MDS promote selfrenewal, leading to a proliferative advantage over normal HSCs and asymptomatic clonal expansion and eventually to overt disease
. Mutations that occur early in disease evolution can be detected by calculating allele frequency in bulk sequencing studies, or by single cell sequencing, and these two approaches correlate well with each other 27 . Using these methods, several studies have demonstrated that, as general groups, the splicing factors (SF3B1, serine and arginine rich splicing factor 2 (SRSF2), U2 small nuclear RNA auxiliary factor 1 (U2AF1) and zinc finger CCCH-type, RNA binding motif and serine/ arginine rich 2 (ZRSR2)) and epi genetic modi fiers, especially DNMT3A and TET2, tend to be mutated early in the evolution of MDS, whereas mutations in transcription factors (runt related transcription factor 1 (RUNX1), GATA binding protein 2 (GATA2) and cut like homeobox 1 (CUX1)) can be either early or late events 26 .
The genes most frequently mutated in CHIP partially correspond to the initiating mutations in MDS. The two most commonly mutated genes in CHIP, DNMT3A and TET2, both encode epigenetic regulators that, when mutated in MDS, tend to occur early in disease pathogenesis 26 . On the other hand, mutations in splicing factors are less common in CHIP than would be expected based on their frequency in MDS. This observation suggests that they may be more morphologically deterministic than mutations in epigenetic regulators and that the patients who acquire splicing factor mutations develop overt dysplasia more rapidly and are thus relatively under-represented in the cohorts of 'healthy' adults in whom CHIP was defined. Other genes mutated frequently in CHIP cohorts are either mutated rarely (CBL) or not yet assessed (protein phosphatase, Mg 12, 21 .
Progression to leukaemia. sAML is a disease distinct from de novo AML, and is characterized by a poorer response to induction therapy, a significantly higher relapse rate and an overall inferior prognosis. Mounting evidence suggests that sAML is also biologically distinct from de novo disease, reflecting its evolution from MDS. Careful study of rigorously defined cases of de novo AML and sAML has shown that mutations in SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, enhancer of zeste 2 (EZH2), BCL6 co-repressor (BCOR, part of a polycomb repressive complex (PRC)) and stromal antigen 2 (STAG2, a component of the cohesin complex) are strongly associated with an antecedent MDS and are thus highly specific for sAML 28 . These mutations define a group of patients with AML that behaves clinically like sAML even in cases when no pre-existing dysplasia or cytopenias have been documented. In contrast, mutations in nucleophosmin (NPM1) and rearrangements involving mixed-lineage leukaemia 1 (MLL1, also known as KMT2A, located at chromosome 11q23) or genes that encode components of the core binding factor are primarily restricted to de novo AML. Most other mutations, including those in DNMT3A, TET2 and RUNX1, are not unique to either disease entity. TP53-mutated AML comprises its own unique category of disease that tends to have fewer cooperating point mutations, which may be functionally replicated by a high frequency of cytogenetic rearrangements that disrupt global chromosomal architecture 9, 28 . Some of the mutations that occur during progression from MDS to AML are found in core haematopoietic transcription factor genes, including RUNX1, GATA2 and CCAAT/enhancer binding protein α (CEBPA), which abrogate normal differentiation 28 . Activating mutations in signalling pathway components such as fms related tyrosine kinase 3 (FLT3) and RAS family members, which control cellular proliferation, also Nature Reviews | Cancer Early mutations tend to lead to increased haematopoietic stem cell (HSC) self-renewal, clonal expansion and the development of clonal haematopoiesis of indeterminate potential (CHIP). As the mutant clone continues to enlarge, it gives rise to an expanding population of cells in which acquisition of additional genetic or epigenetic lesions can promote progression to overt malignancy. These secondary subclonal events tend to lead to the development of overt dysplasia, myelodysplastic syndrome (MDS) and eventually secondary acute myeloid leukaemia (sAML).
Cohesin complex
A multisubunit protein complex that forms a ring structure capable of encircling two chromosomal strands of DNA and is required for sister chromatid cohesion during mitosis.
Core binding factor
A core haematopoietic transcription factor complex, mutations of which are associated with acute myeloid leukaemia in younger patients and a relatively good prognosis.
Red cell distribution width
A measure of the distribution of red blood cell sizes; indicates the degree of variation within a sample.
commonly occur during the progression to sAML, and their subclonal presence in otherwise lower-risk MDS is associated with impending transformation 26, [29] [30] [31] .
Positive and negative cooperativity between mutations.
At the time of diagnosis, most cases of MDS and sAML are clonally and genetically complex, with many clones containing more than three cooperating disease-associated mutations 32 . In MDS, as in other cancers, certain mutations co-occur at frequencies greater than or less than would be expected by chance. These variances are most likely driven by patterns of functional complementarity, redundancy and synthetic lethality. Complementarity is most easily appreciated in cases with mutations in genes from different classes of biological function, as for example, in a patient with TET2, SRSF2 and RUNX1 mutations. On the other hand, certain mutations co-occur much less often than would be expected by chance, which presumably implies either functional redundancy or synthetic lethality, such that co-mutation would have either a neutral or a negative consequence. For instance, the individual splicing factors are almost never co-mutated with each other, and neither are cohesin complex genes 33, 34 . Other combinations of mutations have a relative paucity of cooccurrence, such as ASXL1 and DNMT3A 25, 26, 35 . Definitive functional evidence of mutual exclusivity does not exist for most mutation pairs. In the absence of such evidence, it is therefore important not to overstate the biological basis for these associations.
As discussed above, some specific mutations are associated with the initial development of CHIP, whereas subsequent evolution is probably guided by the temporal acquisition of mutations that cooperate to generate overt malignancy. The timing and context of each serial mutation may influence disease phenotype and progression. This concept has been best described in the MPNs, in which mutations in JAK2 and TET2 co-occur in approximately 10% of patients. Sequencing Nature Reviews | Cancer
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The somatic mutations that drive myelodysplastic syndrome (MDS) increase self-renewal, aberrant differentiation and morphological abnormalities in haematopoietic stem cells (HSCs). The effects of MDS mutations on HSCs are apparent in some mouse models 179 . For example, mutations in or loss of Dnmt3a or Tet2 expand the mutant HSC clone and increase HSC function at the expense of normal polyclonal haematopoiesis 75, 77, 180 . Asymptomatic patients with clonal haematopoiesis of indeterminate potential (CHIP), by definition, have normal blood counts, but many have an elevated mean red cell distribution width, suggesting some dyserythropoiesis even with a single mutation 12 . Certain mutations are associated with specific abnormalities in differentiation, such as the formation of ring sideroblasts in patients with splicing factor 3b subunit 1 (SF3B1) mutations and impaired erythropoiesis and hypolobated micromegakaryocytes in patients with 5q − syndrome 54, 181 . The ineffective haematopoiesis and cytopenias that define MDS may seem paradoxical, as the genetic lesions in MDS give HSCs a clonal advantage, and generally expand progenitor cells, leading to a hypercellular bone marrow. Terminal maturation, however, is impaired, leading to increased apoptosis of differentiating cells and thus peripheral cytopenias (see the figure) .
HSCs exist in a supportive stromal microenvironment comprised of sinusoidal vascular endothelial cells, osteoblasts, adipocytes, and other components, which can also alter HSC function and differentiation [182] [183] [184] . In mice, selective disruption of certain genes only in the stroma, such as deletion of β-catenin (Ctnnb1), the Dicer1 ribonuclease or Sbds, the gene mutated in the Schwachman-Diamond syndrome
, can cause abnormal differentiation of HSCs and the development of dysplasia 185, 186 . This interaction is bidirectional, as myeloid neoplasms can remodel the bone marrow niche, often leading to increased fibrosis 187 . Although in these model systems MDS can be induced purely by stromal defects, it is unclear whether human MDS can be caused by defects isolated to the bone marrow stroma or whether genetic and epigenetic alterations in the HSCs are an essential component of human disease. The fact that MDS can be cured in some cases by transplantation of HSCs alone suggests that the stroma is at least not always the primary disease-initiating element.
Like aplastic anaemia, MDS is often associated with immune dysfunction. Inappropriate immune targeting of haematopoietic progenitors may contribute to the cytopenias observed in some cases of MDS and is another example of an abnormal haematopoietic environment contributing to disease phenotype 188 . Up to 30% of patients with MDS show improvements in their cytopenias following treatment with immunosuppressants, and patients with trisomy 8 are particularly likely to respond to this form of therapy [189] [190] [191] .
Box 3 | Aberrant haematopoiesis, the bone marrow microenvironment and MDS
Polycythemia vera (PV). Myeloproliferative neoplasm characterized by an elevated red blood cell count, and almost exclusively associated with activating mutations in Janus kinase 2 (JAK2).
Essential thrombocythemia (ET).
Myeloproliferative neoplasm characterized by elevated platelet count, associated with mutations in Janus kinase 2 (JAK2), calreticulin (CALR) or MPL (gene that encodes the thrombopoietin receptor).
Ring sideroblasts
Early red cell precursors containing aberrant mitochondrial iron staining; associated with mutations in splicing factors, most commonly splicing factor 3b subunit 1 (SF3B1).
of single cell clones isolated from patients with MPN showed that those with a JAK2 mutation occurring first are more likely to develop polycythemia vera and have increased thrombotic risk, whereas those with a TET2 mutation occurring first are more likely to develop essential thrombocythemia 36 . JAK2 mutations frequently co-occur with SF3B1 mutations in the MDS/MPN overlap syndrome (BOX 1) MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) 1 . As in MPNs, either mutation can occur first, and the original phenotype can subsequently be modified by acquisition of the second mutation 37, 38 . Evolution in response to therapy. Although MDS undergoes clonal evolution even in untreated patients, the administration of disease-altering therapy, such as hypomethylating agents or lenalidomide, functions as an external selective pressure that can influence the relative proportions of coexisting clones. To date, there are limited genetic data for how MDS evolves with treatment, and much of our understanding is extrapolated from related diseases. Analysis of serial AML samples collected at diagnosis and relapse shows that subclones apparent at diagnosis can become undetectable, whereas mutations conferring resistance to therapy may evolve over time through either the acquisition of resistance mutations in the dominant subclone or outgrowth of a pre-existing subclone 39, 40 . In some cases, these resistant subclones can be detected even in samples from patients in remission and provide a source for leukaemic relapse [40] [41] [42] . In cases of AML in which chemotherapy eliminates leukaemic blasts and leaves bone marrow in which there is no morphological evidence of disease, pre-malignant mutations may still be detectable and able to reinitiate disease [41] [42] [43] . It is important to recognize that this post-treatment clonality is an entity distinct from CHIP, carrying a much higher risk of progression to overt leukaemia 28, [41] [42] [43] .
Recurrently mutated pathways
Several studies have used targeted sequencing panels built around genes mutated in other myeloid neoplasms to describe the spectrum of somatic mutations in MDS and their clinical and pathological consequences 9, 25, 26, 44 . Between 75% and 90% of patients have a mutation in at least one known, recurrently mutated gene, and this number will probably increase as additional genes are identified 25, 26 (FIG. 1) .
Mutational processes. MDS arises as a consequence of the sequential acquisition of somatic mutations in
HSCs. It is estimated that HSCs acquire approximately 0.13 exonic single nucleotide variants (SNVs) per year of life 32 . This calculation assumes a constant mutational rate, but it is possible that initiating mutations alter the mutational milieu of the cell, thus shaping the subsequent evolutionary path 26 . The most frequent base-pair change seen in clonal haematopoiesis and MDS is the C>T transition, a hallmark of methylcytidine deamination associated with ageing 12, [45] [46] [47] . Other age-related mutational processes also contribute to the pathogenesis of MDS, including large chromosome rearrangements, the occurrence of small insertions and deletions and progressive telomeric shortening 48 .
Splicing factors.
Alternative splicing of pre-mRNA is a common feature of eukaryotic genes and is one of the most commonly dysregulated processes in cancer 49 . Mutations in components of the spliceosome are the most common recurrent lesions in MDS and are found in up to 60% of cases 50 . The majority are in components of the 3′ spliceosome, including SF3B1, SRSF2, U2AF1 and, to a lesser extent ZRSR2, pre-mRNA processing factor 8 (PRPF8), U2AF2, LUC7 like 2, pre-mRNA splicing factor (LUC7L2) and splicing factor 1 (SF1) 10, 25, 26, [51] [52] [53] (FIG. 3) .
Mutations in SF3B1, SRSF2 and U2AF1 occur exclusively as heterozygous missense mutations at defined hot spots, leading to highly recurrent amino acid substitutions that alter the function of the splicing machinery. SF3B1 mutations, the most common spliceo some alteration in MDS, are highly associated with the presence of ring sideroblasts and a relatively benign prognosis 38, 52 . They lead to altered selection of 3ʹ splice sites and aberrant splicing of important genes involved in iron homeostasis that probably mediate the ring sideroblast phenotype 54, 55 . SRSF2 is the second most commonly mutated splicing factor in MDS and is also frequently mutated in MDS/MPN overlap syndromes. Missense mutations alter SRSF2's binding to exonic splice enhancers, which in turn leads to mis-splicing of several important genes, including EZH2 (REF. 56 ). Mutations in U2AF1 occur in 10-15% of MDS cases, Nature Reviews | Cancer are not associated with any particular morphological phenotype and promote increased exon skipping 51, 57, 58 . Neither SRSF2 nor U2AF1 mutations confer the favourable prognosis associated with mutations in SF3B1 (REF. 38 ). Although these studies have shown that mutations in different splicing factor genes lead to distinct patterns of aberrant splicing and alter the abundance or function of independent sets of target genes, no specific alternatively spliced isoform has been demonstrated to directly cause disease. Furthermore, although the data are still limited, there has been little overlap of altered splicing events reported between mice and humans or between individual spliceosomal mutants, raising the possibility that mutations in these genes could promote MDS through some alternative mechanism.
Epigenetic regulators: DNA methylation and histone modification. Post-translational modifications of DNA and histones are important mechanisms of cellular epigenetic regulation. Mutations in genes involved in these processes are the second most common set of recurrent lesions in MDS.
Methylation of cytosines in repetitive CpG elements in DNA, mediated by the DNA methyltransferases (DNMTs), is one of the most common epigenetic modifications, and functions by altering the accessibility of DNA regulatory regions 59 (FIG. 4) . Inactivating mutations in the gene encoding one such enzyme, DNMT3A, occur in 10-15% of MDS cases 25, 26, 60, 61 . The opposing process, DNA demethylation, is mediated by the ten-eleven translocation (TET) family of proteins, dioxygenases that catalyse the conversion of 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) as part of a multi step reaction that eventually leads to DNA demethyl ation [62] [63] [64] [65] (FIG. 4) . TET2 is one of the most commonly altered genes in MDS, with inactivating mutations found in approximately 30% of cases 25, 59, 66 . These mutations are associated with hypermethylation of cytosines at enhancer sequences and subsequent repression of several genes important for myeloid differentiation [67] [68] [69] .
Alterations in DNA methylation also occur in patients with mutations in the genes encoding the isocitrate dehydrogenase (IDH) enzymes, IDH1 and IDH2, found in approximately 5% of patients with MDS. These mutations produce a neomorphic enzyme that converts isocitrate into R-2-hydroxyglutarate (2HG) instead of α-ketoglutarate (α-KG) 25, 70, 71 . 2HG acts as an onco metabolite and diffuses to the nucleus, where it promotes neoplasia by, among other things, inhibiting α-KG-dependent dioxygenases, including TET2 (FIG. 4) .
The mechanisms by which changes in methylation contribute to the pathogenesis of MDS are complex, and multiple studies have been unable to identify a clear correlation between methylation and gene expression 60, 75 . Although DNMT3A and TET2 are seemingly biochemical opposites, their genes are frequently co-mutated in MDS 25 . Mice deficient in either Dnmt3a or Tet2 have pheno typic similarities and the double mutants show accelerated development of malignancy [75] [76] [77] . Interrogation of the global landscape of 5mC and 5hmC in haematopoietic cells has shown that many genes known to be dysregulated in myeloid malignancies lie within 'canyons' of sparse methylation, where their expression is regulated by epigenetic histone modifications. DNMT3A is important for maintaining the borders of these canyons, but those same borders are also enriched in 5hmC, suggesting synergistic, rather than divergent, roles for TET2 and DNMT3A in this capacity 76, 78 . Genes that encode histone modifying enzymes also contribute to MDS. The covalent modification of histone tails leads to changes in chromatin structure and altered binding of regulatory proteins (FIG. 4) . The PRCs are two distinct protein complexes (PRC1 and PRC2) that are both required for maintaining the transcriptional silencing of key developmental regulators during differentiation. PRC2 trimethylates histone H3 on lysine 27 (H3K27me3), whereas PRC1 ubiquitylates histone H2A at lysine 119; both alterations lead to chromatin compaction [79] [80] [81] . Components of both complexes Nature Reviews | Cancer Red signifies gain-of-function mutations. ASXL1, additional sex combs-like 1; BCOR, BCL6 co-repressor; C, cytosine; 5mC, 5-methylcytosine; 5hmC, 5-hydroxymethylcytosine; DNMT3A, DNA methyltransferase 3A; ETV6, ETS variant 6; EZH2, enhancer of zeste 2; H2AK119Ub, histone H2A lysine 119 ubiquitylation; H3K27, histone H3 lysine 27; H3K27me3, H3K27 trimethylation; IDH, isocitrate dehydrogenase; RUNX1, runt related transcription factor 1; SMC1A, structural maintenance of chromosomes 1A; STAG2, stromal antigen 2; TET2, tet methylcytosine dioxygenase2; WT1, Wilms tumour 1.
can be mutated in MDS. EZH2 encodes a PRC2 catalytic subunit and is mutated in approximately 5% of patients with MDS; loss of Ezh2 promotes the development of MDS in mouse models 25, 82 . BCOR and BCOR-like 1 (BCORL1) are components of a PRC1 complex known as PRC1.1, are mutated in approximately 5% of cases of MDS and are associated with poor prognosis 25, [83] [84] [85] [86] . ASXL1 is recurrently mutated in approximately 20% of patients with MDS 25 . Although not itself a constituent of either PRC, ASXL1 forms a polycomb repressive deubquity lase complex with BRCA1-associated protein 1 (BAP1) that physically interacts with PRC2 and deubiquitylates histone H2A 87, 88 . Pathogenic ASXL1 mutations are restricted to exons 11 and 12, and lead to a truncated protein product that increases the deubiquitylation activity of BAP1, which is associated with decreased global H3K27me3 (REFS 88, 89) . Mutations in EZH2, ASXL1 and BCOR all lead to dysregulation of several important haematopoietic lineage genes, including the homeobox A (HOXA) cluster, possibly explaining their role in promoting dysplasia and cytopenias 82, 88, 90 .
Cohesin complex. The cohesins (STAG2, structural maintenance of chromosomes 3 (SMC3), SMC1A and RAD21) form a ring-shaped multiprotein structure that encircles DNA and helps to maintain sister chromatid cohesion, which in turn prevents collapse of the replication fork and facilitates homologous recombination-mediated DNA repair. Loss-of-function mutations in cohesin genes occur in approximately 15% of MDS cases 25, 26, 34, 91 . Despite the role of these proteins in sister chromatid cohesion, cohesin mutations in MDS are not associated with aneuploidy or chromosomal aberrations 91 . Cohesins also function to stabilize DNA loops that promote interaction between promoters and distant enhancers 92 (FIG. 4) . It is now thought that cohesin mutations drive MDS pathogenesis primarily through dysregulation of long-range chromatin interactions, leading to altered gene expression, rather than through their roles in replication and homologous recombination, although further work is needed to confirm this hypothesis [93] [94] [95] [96] .
Transcription factors.
A small number of core haematopoietic transcription factors are recurrently mutated in MDS. Germline loss-of-function mutations in RUNX1, GATA2 and ETS variant 6 (ETV6) are associated with inherited bone marrow failure disorders that carry a risk of MDS and AML [97] [98] [99] 
. RUNX1 is the DNAbinding subunit of the core binding factor, which regulates several genes involved in haemato poiesis. In addition to germline mutations, somatic mutations are found in approximately 10% of cases of MDS, often associated with severe thrombocytopenia 9, 25, 100, 101 . RUNX1 mutations co-occur with cohesin mutations, as well as in other genetic contexts 26, 91 . GATA2 encodes a zinc finger transcription factor that is highly expressed in HSCs, and is essential for normal haematopoietic differentiation. Like RUNX1, both germline and somatic mutations occur in GATA2, but somatic mutations are present in only 1-2% of patients with MDS 25, 102 . Several other transcription factors are mutated less commonly in MDS. For example, Wilms tumour 1 (WT1) encodes a sequence-specific DNA-binding transcription factor mutated in fewer than 5% of cases of MDS that functions to recruit TET2 to specific genomic loci [103] [104] [105] .
The role of p53 in MDS. TP53 is the most frequently mutated tumour suppressor gene across all human cancers and is recurrently mutated in MDS 49 ( see FIG. 1 ). Humans born with a single mutant allele of TP53, the Li-Fraumeni syndrome, have a dramatically increased risk of many types of cancer, including MDS and AML
. Somatic disruption of TP53 in MDS is strongly associated with low platelet levels, a high blast count, complex karyotype and previous exposure to chemotherapy 9, 28 . Many patients with deletion of one TP53 allele, including cases with del(17p), carry a second inactivating mutation in the other allele of TP53 (REF. 106 ). Loss of TP53 in MDS and AML carries a particularly dismal prognosis 9, 107 . p53 mediates the response to cellular stress by increasing expression of genes involved in apoptosis and cell cycle arrest 108, 109 . This pathway is negatively regulated by the phosphatase PPM1D. Truncating mutations in PPM1D have been identified in CHIP and are found at increased frequency in the blood of patients with ovarian cancer who have previously been treated with chemotherapy 21, 110 . Inappropriate entry into the cell cycle before DNA repair is complete and inadequate activation of the DNA damage repair machinery are believed to contribute to the chemotherapy resistance, accumulation of genomic alterations and chromosomal instability seen in patients with inactivation of the p53 pathway.
Although loss of p53 in vitro can promote aberrant self-renewal in some assays, HSCs with heterozygous inactivation of Trp53 do not have an advantage over normal HSCs in competitive mouse transplant models 111, 112 . However, if those mice are then exposed to alkylating agents or ionizing radiation, the Trp53 mutant clone rapidly expands at the expense of normal HSCs 111, 113 . Indeed, mutations in TP53 are present in approximately 5% of MDS cases, but more than 30% of therapy-related myeloid neoplasms 25, 28, 44, 111, 114 . Of note, TP53 and PPM1D are among the genes most frequently found to be mutated in individuals with CHIP, raising the possibility that detection of somatic mutations in patients scheduled to receive chemotherapy for other cancers could identify those most at risk of developing therapy-related myeloid neoplasms 12, 21 .
Abnormal cell signalling. Mutations in signalling pathway components are associated with pro-proliferative states and occur in a range of myeloid malignancies, including AML (FLT3), polycythemia vera (JAK2), essential thrombocythemia (JAK2 and the gene encoding the thrombopoietin receptor (MPL)), chronic myelomonocytic leukaemia (CMML) (CBL) and mast cell disorders (KIT) [115] [116] [117] [118] [119] . Mutations in these genes all occur at a relatively low frequency in MDS compared with AML, CMML or MPN. Many of these mutations affect the cell through activation of the MAPK pathway, as well as other signalling pathways. Mutations in the MAPK pathway (NRAS, KRAS, neurofibromin 1 (NF1) and protein tyrosine phosphatase, non-receptor type 11 (PTPN11)) are those most frequently found in MDS but still occur in only approximately 10% of cases overall 25, 26 . When such mutations do occur they are typically found in subclonal populations and occur late in disease evolution, often heralding the transition to sAML 30, 31 . Most signalling pathway mutations are missense mutations or involve small insertions or deletions that lead to constitutive activation. One exception to this is the CBL gene, which encodes a tyrosine kinase-associated ubiquitin ligase 120 . CBL mutations lead to upregulation of signalling proteins such as FLT3 and MPL 121, 122 . Although CBL mutations are relatively common in CHIP, they occur less frequently in MDS, perhaps owing to tropism for myelomonocytic lineages, resulting instead in enrichment of MDS/MPN overlap syndromes 123 . When CBL mutations do occur in MDS, they are often late events 12, 21, 26, 118 .
Recurrent cytogenetic rearrangements
Cytogenetic analysis of bone marrow samples from patients with MDS is part of routine clinical practice, and large chromosomal rearrangements are seen in approximately half of cases (TABLE 1, reviewed in detail elsewhere 124 ). Like individual gene mutations, these large-scale copy-number alterations can serve as founding events and drive disease evolution in MDS and AML (reviewed in detail elsewhere 125 ). Acquisition of cytogenetic abnormalities during disease evolution is predictive of a poor prognosis 126, 127 . Elucidation of the pathogenic genes within large chromosomal deletions has been challenging. Among those that are most common and best understood are isolated deletion of 5q, loss of chromosome 7 and deletion of 17p (discussed above with TP53).
Chromosome 5q deletions. The single most common isolated cytogenetic abnormality in MDS is deletion of chromosome 5q. Patients with MDS with isolated deletions of chromosome 5q often have a consistent clinical pheno type, termed the 5q − syndrome, which is more common in women and has a relatively indolent course 128, 129 . Deletion of 5q leads to haploinsufficiency of a small number of genes, including ribosomal protein S14 (RPS14), casein kinase 1 α1 (CSNK1A1), adenomatous polyposis coli (APC), heat shock protein family A (HSP70) member 9 (HSPA9), early growth response 1 (EGR1), DEAD-box helicase 41 (DDX41), NPM1, TRAF-interacting protein with forkhead-associated domain B (TIFAB), Diaphanous-related formin 1 (DIAPH1), microRNA (miR)-145 and miR-146a, most of which lack evidence of bi-allelic inactivation [130] [131] [132] [133] [134] [135] [136] . A small subset of cases also have point mutations in CSNK1A1 or DDX41, but no other genes have been identified with bi-allelic deletion or mutation [137] [138] [139] . Targeted short hairpin RNA (shRNA) screening of the genes in the commonly deleted region in 5q − syndrome demonstrated that loss of RPS14 leads to a block in pre-ribosomal RNA (rRNA) processing and abnormal 
Conditioning regimens
High-dose preparative chemotherapy regimens given before stem cell transplantation. Can be either myeloablative (doses sufficient to completely ablate the bone marrow) or non-myeloablative.
erythroid differentiation that phenocopies the macrocytosis and anaemia seen in the 5q − syndrome 140 . Mouse models with conditional heterozygous inactivation of Rps14 display a similar erythroid defect that is p53 dependent and accompanied by upregulation of components of innate immune signalling 141, 142 . This is a similar mechanism to that proposed for DiamondBlackfan anaemia, caused by germline heterozygous inactivation of ribosomal protein genes 143 
. An abundance of evi dence now indicates that the full clinical phenotype of 5q − MDS is caused by combinatorial haploinsufficiency of multiple factors 133, 144 . Another important gene involved in the pathogenesis of 5q − syndrome is CSNK1A1, which encodes a serine/ threonine kinase that when heterozygously deleted leads to upregulation of WNT signalling and stem cell expansion 139, 145 . Homozygous deletion of CSNK1A1, on the other hand, leads to the accumulation of p53 and loss of the competitive advantage seen in the heterozygous setting. It is this dose-dependent effect of CSNK1A1 that leads to one of the hallmark features of 5q − syndrome: its responsiveness to treatment with the thalidomide derivative lenalidomide 146 (FIG. 5) . Lenalidomide binds to the substrate recognition component (cereblon, CRBN) of the Cullin-RING E3 ubiquitin ligase CRL4, altering its substrate affinity and leading to the selective degradation of the CSNK1A1 gene product, CK1α (REFS 145, 147) (FIG. 5) . Loss of CK1α leads to activation of p53 and apoptosis, and knockdown of TP53 abrogates the effect of lenalidomide in vitro 139, 145 . Chromosome 7 deletions. Deletion of 7q and/or monosomy 7 are also common in MDS and are associated with a poor prognosis 6 . Like deletion of 5q, these chromosomal aberrations lead to haploinsufficiency of several genes implicated in haematological malignancies, including EZH2, CUX1 and MLL3 (also known as KMT2C), which encodes a histone H3 lysine 4 (H3K4) methyltransferase [148] [149] [150] . In mouse models, Mll3 haploinsufficiency cooperates with mutations in the RAS pathway and Trp53 to promote leukaemia 148 .
Genetics and MDS management
The standard backbone of therapy for MDS involves supportive measures such as transfusion, infection control, growth factor support and iron chelation. The use of disease-altering therapy, including lenalidomide, 5-azacitidine, decitabine or allogeneic HSC transplantation (alloHSCT), is based on careful evaluation of the individual patient, including age, prognostic risk stratification and genetics 18 .
Genetic predictors of response to therapy. The hypomethylating agent 5-azacitidine and its derivative 5-aza-2ʹ-deoxycytidine (decitabine) inhibit DNMTs and thus lead to global hypomethylation. Both drugs are active in MDS, and 5-azacitidine improves overall survival when compared with standard supportive care in patients at higher risk as defined by the IPSS 151, 152 . Molecular analysis may help to predict which patients will benefit the most from these therapies. Loss of TET2 across the entire MDS clone predicts improved response to hypomethylating agents, which may be related to the finding that these patients often have low-risk disease. The presence of additional mutations, such as in ASXL1, are associated with a poorer prognosis, and subclonal TET2 mutations do not similarly predict for response to treatment 103, 153 . Isolated deletion of chromosome 5q predicts response to treatment with lenalidomide, which leads to complete cytogenetic remission in more than half of patients and a reduced need for transfusions in 75% of those treated 146 . As discussed above, lenalidomide functions via selective degradation of CK1α, leading to acti vation of p53. TP53-mutant subclones can often be detected in pretreatment samples and expand following treatment with lenalidomide, leading to the development of resistance 154 . This may also explain the lack of efficacy of lenalidomide in patients with 5q deletion in the setting of complex karyotypes or in AML, as many of these patients are likely to carry concomitant mutations in TP53. The molecular correlates of response to lenalidomide in patients with non-5q − syndrome (approximately 25% become transfusion independent in this context) are not known 155 .
Allogeneic bone marrow transplantation. The only curative treatment for MDS is alloHSCT. Although some patients receive myeloablative conditioning regimens, recent studies showing equivalent success rates with reduced-intensity regimens suggest that the primary mechanism of action is immunological elimination of . The efficacy is far from complete, however, and specific mutations have been associated with poor survival following alloHSCT, including TP53, owing to increased rates of post-transplant relapse 35, 157 . TP53 mutation is a powerful marker of poor survival after transplant: in a retro spective analysis of 87 patients, not one of the 18 with a TP53 mutation was still alive 5 years after alloHSCT with reduced-intensity conditioning regimens 35 . Interestingly, the rare patients with a complex karyotype who lack a concomitant TP53 mutation have a similar prognosis to patients with a normal karyotype 35 .
Clinical implications of molecular genetics.
A more complete understanding of MDS genetics can inform multiple aspects of our clinical practice, including diagnosis, prognosis and prediction of response to therapy. First, although morphological analysis is still required to diagnose MDS, it is evident that morphology often directly relates to the underlying genetic lesions. It is likely that genetics will have an increasing role in the diagnosis of MDS in coming years as accumulating evidence strengthens the association between specific mutations and clinicopathological features of the disease. It is also clear that certain mutations influence the prognosis of patients with MDS. Initial attempts to integrate mutational data into the IPSS have demonstrated improved accuracy in predicting overall survival, and large-scale international collaborations are now under way to fully incorporate molecular genetics into the next generation of prognostic scoring systems 33 . As discussed above, specific mutations may predict response to standard therapies such as hypomethylating agents, lenalidomide and alloHSCT, and prospective studies are needed to validate these findings. Finally, understanding the molecular underpinnings of MDS can aid in the development of new targeted therapies. Targeting epigenetic modifiers and splicing factors is an attractive option, as mutations in these are often founding events. For example, small-molecule inhibitors of neomorphic IDH1 and IDH2 enzymes have shown initial promising results and induce differentiation of primary AML cells in vitro 158, 159 . IDH mutations also lead to increased sensitivity to pro-apoptotic BH3 mimetics, such as the small-molecule BCL-2 inhibitor venetoclax, probably owing to altered mitochondrial function related to elevated 2HG 160 . Initial attempts to target epigenetic regulation with histone deacetylase inhibitors have thus far not shown clinical efficacy 161 . MDS cells carrying mutations in splicing factors may be uniquely sensitive to further inhibition of splicing via mechanisms probably analogous to haploinsufficiency, and this observation has led to the development of smallmolecule splicing inhibitors 162 . Clinical trials of these agents are expected to begin soon.
Conclusions
The rapid accumulation of genetic data over the past decade has provided a molecular taxonomy of MDS, a guide to the genetic progression of CHIP to MDS and MDS to sAML, and the identification of core molecular processes that are functionally disrupted through somatic mutations. CHIP, a pre-malignant condition, is common in older adults and is associated with a specific subset of mutations, most commonly in DNMT3A, TET2, ASXL1, TP53 and SF3B1, suggesting that mutations in these key genes are important for initiating disease. In contrast, mutations in haematopoietic transcription factors and activated signalling pathways tend to occur during disease progression to high-risk MDS and sAML. Patterns of cooperativity and mutual exclusivity act to define the evolutionary path from disease initiation to leukaemia, and it is now clear that clinical phenotype, prognosis and response to therapy in MDS are influenced by combinations of genetic lesions and the order and context in which they occur. Further understanding of these relationships will enable refined prognostic staging models, the identification of patients most likely to respond to therapy and the development of new targeted therapeutics.
